Lucid Diagnostics Seeks Clear Path To US Reimbursement For Esophageal Precancer Test
Test Targets Unmet Need For GERD Patients At Risk Of Developing Precancer And Cancer
Lishan Aklog, CEO of New York-based Lucid Diagnostics, has a long-term vision to provide the paradigm of prevention-to-treatment care for esophageal cancer. In the short term, the company anticipates a favorable outcome from an upcoming pivotal Medicare assessment of its early screening technology.
